Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference t

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023. All

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences:

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members from Satellos’ management team will host investor meetings at the Leerink Partners Global Biopharma Conference 2024 being held from Monday, March 11 to Wednesday, March 13 in Miami, Florida.

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of musc

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has been named as one of the top performers on the TSX Venture Exchange.

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking oral presentation and a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Cl

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trad

VANCOUVER, BC, Feb. 13, 2024 /CNW/ -TSX VENTURE COMPANIES

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapu

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Alan K. Jacobs, M.D., Chief Medical Officer (CMO), has left the Company to pursue other opportunities. Satellos has engaged Jordan Dubow, M.D., to lead the development of clinical trial strategy for the Company’s lead program in Duchenne muscular dystrophy in the role of Chief Medical Advisor.

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and to list its common shares (the “Common Shares”) on the TSX.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending September 30, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted.

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Piper Sandler 35th Annual Healthcare Conference

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a publicly traded biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the following updates: AAK1 is the drug target of the Company’s lead drug program in Duchenne muscula

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Stifel 2023 Healthcare Conference taking place November 14

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New York City.

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has entered into an agreement with ICP Securities Inc. ("ICP"), a dealer member in good standing with the Canadian Investment Regulatory Organization, to provide market making services for the securities of Satellos Bioscience Inc. in accordance with TSX Venture Exchange ("TSXV") policies, subject to the receipt of approval by the TSXV. The services agreement aims to assist in maintaining a reasonable market and improving the liquidity of Satellos securities. The Company has agreed to pay a service fee of $7,500 per month for an initial term of four months. There are no performance factors contained in the agreement and ICP will not receive shares or options as compensation.

Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Elizabeth (Liz) Williams, CPA, CA, as Chief Financial Officer (CFO). Warren Whitehead, CPA, CMA, who has served as CFO for Satellos for two years, will now become Head of Corporate Strategy. These management updates were effective as of September 1, 2023.

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients

TORONTO, Aug. 21, 2023 /CNW/ - Frank Gleeson, Chief Executive Officer, Satellos Bioscine (TSXV: MSCL) ("Satellos" or the "Company") shares his Company's story in an interview with TMX Group.

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with Duchenne

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the results of its annual general meeting of shareholders held virtually on June 29, 2023 (the "Meeting"), as well as the adoption of amendments to the Company's Stock Option Plan.

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023

Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 5,732,797 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.60 per share for a period of 10 years from the date of the grant.

Toronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending March 31, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted. Satellos' interim condensed consolidated financial statements for the three months ended March 31, 2023, and the related management's discussion and analysis (MD&A) are available on SEDAR at www.sedar.com.

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a short form prospectus dated May 9, 2023. Bloom Burton purchased the Shares at a price of $0.50 per Share for total consideration of $726,535 and its affiliate acquired the Compensation Options as partial consideration for its services in connection with the public offering. Combined with other treasury issuances of Shares by the Corporation, this resulted in a decrease of beneficial holdings of approximately 4.9% of the outstanding Shares on a partially diluted basis since the date of the last early warning report.

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securities for gross proceeds of $55 million (the "Offering"). The Offering included participation from funds managed by Avidity Partners, Qiming Venture Partners USA, Perceptive Advisors, Soleus Capital, FMB Research, Allostery Investments and other leading healthcare specialized institutional investors.

Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce today that it has filed its final short form prospectus (the "Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with the Company's previously announced public offering of common shares of the Company ("Common Shares") (or pre-funded common share purchase warrants ("Pre-Funded Warrants" and, together with the Common Shares, the "Securities") of the Company in lieu of Common Shares) (the "Offering").

VANCOUVER, BC, April 19, 2023 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - April 19, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the pricing and terms of its previously announced best efforts public offering of common shares of the Company ("Common Shares") (or pre-funded common share purchase warrants ("Pre-Funded Warrants" and, together with the Common Shares, the "Securities") of the Company in lieu of Common Shares) (the "Offering").

VANCOUVER, BC, April 19, 2023 /CNW/ - The following issues have been halted by IIROC:

Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of common shares of the Company ("Common Shares") (or pre-funded common share purchase warrants ("Pre-Funded Warrants") of the Company in lieu of Common Shares) (the "Offering"). Each Pre-Funded Warrant issued in lieu of a Common Share at the election of any purchaser (together with the Common Shares, the "Securities") entitles the holder thereof to acquire one common share (a "Warrant Share") at a nominal exercise price for a period of 60 months following the closing of the Offering. The number of Securities to be distributed, the price of each Security and the size of the Offering will be determined by negotiation between the Company and the Agent (as defined herein) in the context of the market with final terms to be determined at the time of pricing. The Offering will be led by Bloom Burton Securities Inc. (the "Agent") on a best efforts agency basis.

Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the year ending December 31, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced it has closed its previously announced non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") for gross proceeds of $2,385,000 (the "Offering"). The Company will use the proceeds of the Offering for corporate and general working capital purposes.

Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the "Offering") of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos initially proposed to raise gross proceeds of up to $2,250,000. The Company has now increased the size of the Offering to $2,385,000. The Company expects to use the proceeds of the Offering for corporate and general working capital purposes.

Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit

Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos proposes to raise gross proceeds of up to $2,250,000 (the "Offering"). The Company expects to use the proceeds of the Offering for corporate and general working capital purposes.

Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results from further preclinical studies using the Company's lead drug candidate SAT-3153.

Toronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce results from multiple preclinical studies in a disease model of Duchenne muscular dystrophy ("Duchenne"). An updated corporate presentation has been posted to the Company's website (www.satellos.com).

- SAT-3153 Designated for pre-IND Studies -

Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, and the related management's discussion and analysis (MD&A) are available on SEDAR at www.sedar.com.

-Proof of concept studies to be completed by YE-

- Advancements on the Company's evaluation of potential new disease indication

Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 815,750 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.325 per share for a period of 10 years from the date of the grant.

Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a joint venture company, NW Micelle Therapeutics Inc. ("NWMT"), for the purpose of developing an oral formulation of cannabidiol for the treatment of insomnia and other indications in the mental health sphere ("Oral CBD").

Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that its common shares have commenced trading on the OTCQB Venture Market ("OTCQB") under the symbol "MSCLF". Shares in Satellos will continue to trade on the TSXV under the symbol MSCL.

Toronto, Ontario--(Newsfile Corp. - September 28, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its board of directors (the "Board") has appointed Philip Lambert, Ph.D., as Chief Technology Officer ("CTO") of the Company, effective September 27, 2022.

Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the closing of its previously announced public offering (the "Offering") of units of the Company ("Units"), whereby an aggregate of 8,750,000 Units were issued at a price of $0.40 per Unit, raising gross proceeds of $3,500,000. Each Unit consisted of one common share of the Company (each, a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant"), with each Warrant being exercisable into one Common Share at a price of $0.60 until expiry on September 13, 2025.

Toronto, Ontario--(Newsfile Corp. - September 7, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed its final short form prospectus (the "Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with the Company's previously announced public offering of units ("Units") at a price of $0.40 per Unit for minimum aggregate gross proceeds of $3,500,000 and maximum gross proceeds of $5,000,000 (the "Offering").

Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has priced its previously announced proposed offering (the "Offering") of units of the Company ("Units"). Pursuant to the Offering, the Company will issue Units at a price of $0.40 per Unit for total minimum aggregate gross proceeds of $3,500,000 and maximum gross proceeds of $5,000,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share for a period of thirty-six (36) months from the date of issuance of such Warrant, at an exercise price of $0.60, subject to and in accordance with the terms and conditions of the warrant indenture to be entered into between the Company and Computershare Trust Company of Canada (the "Warrant Indenture"), including acceleration and adjustment in certain circumstances.

Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed an amended and restated preliminary short form prospectus (the "Amended and Restated Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario, amending and restating the Company's preliminary prospectus dated July 11, 2022. The Amended and Restated Preliminary Prospectus has been filed in connection with the previously announced proposed offering of units of the Company ("Units") for minimum aggregate gross proceeds of $3,500,000 and maximum gross proceeds of $5,000,000 (the "Offering"). Each Unit consists of one common share of the Company ("Common Share") and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at any time until for a period of thirty-six (36) months from the date issued. The price of the Units will be determined by negotiation between the Company and the Agents (as defined herein) in the context of the market with the final pricing terms to be determined at the time of filing the final prospectus in connection with the Offering.

Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, filed its financial and operating results on 29 August 2022 for the quarter ended June 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended June 30, 2022, and the related management's discussion and analysis (MD&A) are available on SEDAR at www.sedar.com.

Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been awarded a seven-figure, five-year grant from the Canadian Institutes of Health Research (CIHR).

Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has had new research published in the most recent edition of Nature Communications. The article, titled "GLI3 regulates muscle stem cell entry into GAlert and self-renewal", looks at the critical role that GLI3 plays in satellite cell formation and new findings on its potential to regulate muscle stem cell activation and fate.

Toronto, Ontario--(Newsfile Corp. - July 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of units of the Company ("Units"), comprised of common shares and common share purchase warrants (the "Offering"). The number of Units to be distributed, the price and composition of each Unit, the size of the Offering and the exercise price of each warrant will be determined by negotiation between the Company and the Agents (as defined herein) in the context of the market with final terms to be determined at the time of pricing.

Toronto, Ontario--(Newsfile Corp. - June 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has licensed a provisional patent application, recently filed with the United States Patent and Trademark Office and titled "MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION," from the Ottawa Hospital Research Institute ("OHRI").

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT:...

Toronto, Ontario--(Newsfile Corp. - June 22, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been admitted as a Fellow of the Royal Society, the UK's national science academy and a Fellowship of the world's most revered scientists. With admission to the Royal Society, founded in 1660 by grant of royal charter by King Charles II, Dr. Rudnicki joins an exclusive collective of Fellows including some of the most influential and respected scientists of all time, including Sir Isaac Newton and Charles Darwin.

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, Founder and...

Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been named one of only three 2022 recipients of a prestigious grant awarded from Defeat Duchenne Canada, the country's only national charity dedicated to ending Duchenne muscular dystrophy ("Duchenne").

Presentation on Tuesday, June 7th, at 10:00 AM PT

Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutic drugs that change the way degenerative muscle diseases are treated, today announced its unaudited financial results and operational highlights for the quarter ended March 31, 2022 ("Q1 2022"). All dollar amounts in this press release are in Canadian dollars unless otherwise noted.

Toronto, Ontario--(Newsfile Corp. - April 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ending December 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos Bioscience was invited to present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. The conference brings together U.S., Canadian, and international investors interested in the latest developments in the Canadian healthcare sector.

Ryan Mitchell, PhD and Director of Business Development to highlight advancements with Satellos' novel muscle regeneration technology on April 25-26 in Gouvieux, France

Michael Rudnicki, PhD and Chief Scientific Officer to highlight new advancements with Satellos' novel muscle regeneration technology on March 30

Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress in designing and developing the world's first small molecule drug candidates intended to restore the body's innate cycle of muscle regeneration.

Toronto, Ontario--(Newsfile Corp. - March 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress towards monetizing its novel and proprietary oral pharmaceutical transport technology ("OralTransTM").

Ryan Mitchell, PhD and Director of Business Development to highlight new advancements with Satellos' novel muscle regeneration technology

Satellos Bioscience Inc. (TSX-V: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, Founder and...

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10th. This virtual event will showcase live company presentations and interactive...

Toronto, Ontario--(Newsfile Corp. - February 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually.

Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - Satellos Bioscience Inc. (TSXV: MSCL)

Toronto, Ontario--(Newsfile Corp. - January 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present virtually at the Biotech Showcase™ 2022 conference and conduct virtual one-on-one meetings with investors during the conference.

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Collaborative research program will assess potential for Satellos drug candidates to treat rare dystrophic disease indications

TORONTO, Dec. 15, 2021 /PRNewswire/ -- Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, Founder and CEO, will present live at VirtualInvestorConferences.com on December 16th.

Toronto, Ontario--(Newsfile Corp. - December 6, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Dr. Rima Al-awar, PhD and Mr. Adam Mostafa to its board of directors on December 5, 2021.

Toronto, Ontario--(Newsfile Corp. - November 29, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company, formerly known as iCo Therapeutics Inc. ("iCo"), aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the quarter ended September 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Toronto, Ontario--(Newsfile Corp. - October 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation") is pleased to announce that it has entered into an investor relations agreement (the "Investor Relations Agreement") with BND Projects Inc. ("BND") whereby BND will provide strategic investor relations services. BND will aid the Corporation in building awareness in the financial community by introducing, maintaining and protecting relationships between the management of the Corporation and professional investors.

TORONTO, Sept. 28, 2021 /CNW/ - Frank Gleeson, President and Chief Executive Officer, Satellos Bioscience Inc., ("Satellos") (TSXV: MSCL), and his team joined Arne Gulstene, Head of TSX Company Services, TMX Group, to celebrate the Company's new listing on TSX Venture Exchange and open the market.

Toronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) (Satellos" or the "Company"), a regenerative medicine company focused on the treatment of Duchenne muscular dystrophy and other degenerative or muscle wasting disorders, is pleased to announce that the Company's board of directors has appointed J. Robert Hall, CFA as Vice-President, Finance & Administration.

Toronto, Ontario--(Newsfile Corp. - September 13, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), a regenerative medicine company focused on the treatment of degenerative muscle disorders, announced today core findings from additional preclinical drug development studies in their lead program to treat Duchenne muscular dystrophy ("Duchenne").

Toronto, Ontario--(Newsfile Corp. - September 7, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), and Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, are proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne.

Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics Inc. ("iCo"), today filed financial results and MD&A reports for the second quarter which ended on June 30, 2021, on SEDAR. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards.

Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy ("Duchenne").

Toronto, Ontario--(Newsfile Corp. - August 18, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics, Inc., and NW PharmaTech Limited ("NW PharmaTech") announced today that Amphotericin B Technologies, Inc. ("AmpB Tech"), a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology ("OralTransTM"), has entered into a Joint Development Agreement with NW PharmaTech to develop an oral formulation of cannabidiol ("CBD") for the over-the-counter market. Oral CBD will initially target the global market for sleep aids, estimated at $3 billion in 2020. NW PharmaTech has agreed to provide an up-front payment and fund development costs of the formulation and testing for safety, toxicity and pharmacokinetics.

VANCOUVER, BC, Aug. 17, 2021 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following the receipt of the final order of the Supreme Court of British Columbia on August 5, 2021, and subject to the final approval of the TSX Venture Exchange (the "TSXV"), of the previously announced reverse takeover transaction which was completed by way of plan of arrangement under Section 192 the Canada Business Corporations Act (the "CBCA") involving Satellos Bioscience Inc. ("Pre-Arrangement Satellos") and iCo Therapeutics Inc. ("iCo") (the "Arrangement" or the "Transaction"). It is expected that, following the anticipated issuance of the final bulletin of the TSXV, trading of Satellos Shares will resume on Wednesday August 18, 2021.